F-61 (Wuhan Institute of Biological Products/China Biotechnology/Infectious Disease Hospital of Wuhai)

N/A

Report date: 2025/01/26 18:00:44

Base Information

Drug NameF-61 (Wuhan Institute of Biological Products/China Biotechnology/Infectious Disease Hospital of Wuhai)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionCoronavirus spike glycoprotein modulators
TargetsCoronavirus spike glycoprotein
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesWuhan Institute Of Biological Products Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesInfectious Disease Hospital Of WuhaiChina National Biotec Group Co LtdWuhan Institute Of Biological Products Co Ltd
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A